IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

RUMI, MARIAGRAZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.722
NA - Nord America 9.609
AS - Asia 8.814
Continente sconosciuto - Info sul continente non disponibili 1.428
SA - Sud America 799
AF - Africa 205
OC - Oceania 44
Totale 33.621
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.182
GB - Regno Unito 5.226
CN - Cina 2.530
SG - Singapore 2.324
DE - Germania 2.010
IT - Italia 1.650
SE - Svezia 915
BD - Bangladesh 899
RU - Federazione Russa 817
HK - Hong Kong 746
VN - Vietnam 725
BR - Brasile 531
IN - India 477
FR - Francia 418
UA - Ucraina 398
TR - Turchia 367
CA - Canada 316
IE - Irlanda 295
NL - Olanda 293
KR - Corea 243
FI - Finlandia 222
EU - Europa 187
DK - Danimarca 132
CO - Colombia 115
ID - Indonesia 108
JP - Giappone 77
CI - Costa d'Avorio 66
PL - Polonia 61
AR - Argentina 60
GR - Grecia 56
BE - Belgio 43
IQ - Iraq 40
PK - Pakistan 38
MX - Messico 36
UZ - Uzbekistan 35
AU - Australia 34
AT - Austria 33
CH - Svizzera 31
IR - Iran 31
ZA - Sudafrica 29
CL - Cile 27
EG - Egitto 27
RO - Romania 25
TW - Taiwan 25
ES - Italia 22
EC - Ecuador 21
CR - Costa Rica 20
MA - Marocco 19
MY - Malesia 17
PH - Filippine 16
VE - Venezuela 16
KE - Kenya 15
TH - Thailandia 15
JM - Giamaica 14
SA - Arabia Saudita 14
IL - Israele 13
PE - Perù 12
AE - Emirati Arabi Uniti 11
JO - Giordania 10
AZ - Azerbaigian 9
PT - Portogallo 9
PY - Paraguay 9
TN - Tunisia 9
UG - Uganda 9
CZ - Repubblica Ceca 7
ET - Etiopia 7
NO - Norvegia 7
NP - Nepal 7
NZ - Nuova Zelanda 7
BG - Bulgaria 6
BY - Bielorussia 5
GT - Guatemala 5
KZ - Kazakistan 5
BB - Barbados 4
CY - Cipro 4
DO - Repubblica Dominicana 4
EE - Estonia 4
GE - Georgia 4
HN - Honduras 4
HU - Ungheria 4
KG - Kirghizistan 4
MD - Moldavia 4
OM - Oman 4
PA - Panama 4
SC - Seychelles 4
SK - Slovacchia (Repubblica Slovacca) 4
TT - Trinidad e Tobago 4
AL - Albania 3
IS - Islanda 3
KW - Kuwait 3
LT - Lituania 3
LV - Lettonia 3
LY - Libia 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
DZ - Algeria 2
Totale 32.327
Salva come PNG Salva come JPEG
Città #
Southend 4.918
Singapore 1.297
Ashburn 958
Chandler 721
Hong Kong 678
Beijing 552
Frankfurt am Main 532
San Jose 499
Seattle 462
Milan 440
Council Bluffs 385
Santa Clara 353
Princeton 330
Jacksonville 308
Dublin 290
Wilmington 285
Los Angeles 252
New York 231
Ann Arbor 229
Dallas 224
Fairfield 217
Ho Chi Minh City 210
Dearborn 196
Bengaluru 184
Hanoi 175
Nanjing 172
Toronto 171
Woodbridge 168
Hanover 161
Mountain View 159
Redmond 158
Houston 152
Lauterbourg 145
Boardman 144
Buffalo 135
Serra 131
Somerville 118
Des Moines 116
Andover 115
Moscow 106
Shanghai 106
Sakarya 105
Bogotá 101
Hefei 94
Jinan 93
Cambridge 91
Guangzhou 90
Berlin 82
Helsinki 80
Rome 80
Munich 70
Phoenix 69
Shenyang 68
Abidjan 66
Columbus 55
Tokyo 55
Nanchang 54
Istanbul 53
Jakarta 52
Redwood City 50
The Dalles 48
Tianjin 48
São Paulo 47
Turin 47
Warsaw 47
Naples 46
Cangzhou 45
Jiaxing 43
Hebei 42
Saint Petersburg 42
Da Nang 41
Brussels 40
Dong Ket 40
Hangzhou 38
Athens 37
Changsha 34
Eitensheim 34
Grafing 31
Ottawa 31
Mumbai 30
Kunming 29
London 29
Zhengzhou 29
Haiphong 28
San Diego 28
Shenzhen 27
Chicago 26
Fremont 25
Fuzhou 25
Hamburg 25
Margão 25
Segrate 25
Nuremberg 24
Bitonto 23
Bologna 23
Pisa 23
Atlanta 22
Auburn Hills 22
Piscataway 22
Brooklyn 21
Totale 19.903
Salva come PNG Salva come JPEG
Nome #
Forecasting Hepatitis C liver disease burden on real life data: Does the hidden iceberg matter to reach the elimination goals? 699
Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients 423
Management of HCV-Related Liver Disease in Hemophilia and Thalassemia 412
Prevalence of psychiatric disorders during PEG – Interferon and Ribavirin therapy in patients with chronic hepatitis HCV-correlated 409
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent 362
Anti-LAV/HTLV-III antibodies in groups of individuals at high risk for infection in Italy 353
Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance 338
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 335
High rates of 30-day mortality in patients with cirrhosis and COVID-19 325
The international autoimmune hepatitis group scoring system in patients with chronic hepatitis C and serum autoantibodies undergoing interferon/ribavirin therapy : a prospective validation study 305
A 28-Year Study of the Course of Hepatitis Delta Infection : A Risk Factor for Cirrhosis and Hepatocellular Carcinoma 302
Onset of inflammatory bowel disease during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases 299
Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma 285
Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon 283
Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients 280
Evaluation of three “beyond Baveno VI” criteria to safely spare endoscopies in compensated advanced chronic liver disease 280
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegykated interferon-α2A in chronic hepatitis C : an in vitro and in vivo study 279
Outbreak of Acute Hepatitis A involving young men in Lombardy region, Italy: Risk factors, clinical and virological characteristics 279
Hepatitis C virus deletion mutants are found in individuals chronically infected with genotype 1 hepatitis c virus in association with age, high viral load and liver inflammatory activity 278
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 274
Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy 270
Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving telaprevir 267
Anti-LAV/HTLV-III antibodies in high and low risk groups 263
Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C 263
The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia 260
Anemia during pegylated interferon-ribavirin therapy results from both increase suppression of erythroid differentiation and hemolysis 253
Anemia during peginterferon-ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis 253
The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy 252
Transmission of hepatitis G virus in patients with angioedema treated with steam-heated plasma concentrates of C1 inhibitor 251
US features of liver surface nodularity as a predictor of severe fibrosis in chronic hepatitis C 250
Recovery after L-DOPA treatment in peg-interferon and ribavirin induced parkinsonism 249
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C 248
Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C 243
Natural history and clinical impact of cryoglobulins in chronic hepatitis C : 10-year prospective study of 343 patients 242
The candidate HCV E1E2MF59 vaccine is safe in chronic hepatitis C patients and accellerates the second phase viral decline upon primary response to peg-interferon-2A/ribavirin therapy 239
The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies 239
The natural history of portal hypertension in patients with HCV related compensated cirrhosis undergoing interferon ribavirin therapy 235
Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients 235
Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study 235
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegylated interferon-alpha 2a in chronic hepatitis C : an in vitro and in vivo study 234
Genotype dependent pattern of peginterferon alfa-2b/ribavirin treatment failure in hepatiti sC virus infected patients with cirrhosis : a single center study of 471 naive patients 234
Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs : high rates of sustained virologic response to pegylated interferon and ribavirin therapy 233
Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4 233
Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy 233
A sequential predictive algorithm combining APRI and transient elastography (TE) for diagnosing liver fibrosis in chronic hepatitis C 230
Ribavirin impairs salivary gland function in hepatitis C patients during combination treatment with pegylated interferon alfa-2a 230
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 229
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 229
Case Report: A Challenging Localization of a Pulmonary Ectopic ACTH-Secreting Tumor in a Patient With Severe Cushing’s Syndrome 228
Primary prophylaxis of variceal bleeding in cirrhotic patients : a cohort study 227
Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B 226
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 226
Predictors of psychopathological outcome during peg-interferon and ribavirin therapy in patients with chronic HCV-correlated hepatitis 226
Serum hepatitis B virus DNA detects cryptic hepatitis B virus infections in multitransfused hemophilic patients 225
In vivo and in vitro effect of ribavirin and interferon on erythropoiesis in patients with hepatitis C 225
Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection : a predictor of spontaneous viral clearance and sustained virological response 222
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection 222
Genotype dependent pattern of Peginterferon alfa-2B/Ribavirin treatment failure in hepatitis C virus infected patients with cirrhosis : a single centre study of 471 naïve patients 219
Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3α hepatitis C virus infection 215
NPLA3 I148M polymorphism, steatosis, liver damage, and treatment response in chronic hepatitis C 215
Accelerated schedule of hepatitis B vaccination in patients with hemophilia 213
The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype 212
Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients : a single-centre study 212
The diagnostic accuracy of fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with an SVR 211
The influence of liver fibrosis on the outcome of pegylated interferon and ribavirin anti-hac therapy : a sub-analysis of the mist study 210
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 210
Randomized Study of Peginterferon-alpha2a Plus Ribavirin vs Peginterferon-alpha2b Plus Ribavirin in Chronic Hepatitis C 209
A morphometric and immunohistochemical study to assess the benefit of an svr in hcv cirrhotic patients 208
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegylated interferon-α2a in chronic hepatitis C: an in vitro and in vivo study 208
The candidate HCV E1E2MF59 vaccine enhances 2nd phase viral decline in responders to PEG-IFN/ribavirin 207
Hepatitis C virus genotypes and patterns of peginterferon alfa-2b/ribavirin treatment failure in patients with cirrhosis : a single center study of 471 naïve patients 207
Outbreak of acute hepatitis A involving young men in Lombardy Region, Italy: risk factors, clinical and virological characteristics 207
In vitro effect of ribavirin and pegylated interferon on erythropoiesis 206
Accuracy of FIB-4 to Detect Elevated Liver Stiffness Measurements in Patients with Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study in Referral Centers 205
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis 205
A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort 200
The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis 200
Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c : a retrospective cohort study of 206 untreated patients 197
In vivo and in vitro effect of ribavirin and pegylated-interferon on erythropoiesis in patients with hepatitis C 196
Increased risk of hepatocellular carcinoma in HCV (+) non responder cirrhotics with high liver cell proliferation 196
Increased survival of patients with HCV-related cirrhosis with a long-term response to interferon therapy 195
PNPLA3 I148M polymorphism, steatosis, liver damage, and treatment response in chronic hepatitis C 195
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study (PLoS ONE (2017) 12: 2 (e0172159) DOI: 10.1371/journal.pone.0172159) 195
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 195
Imatinib in CML patients HBCAB and/or HCVAB positive : report of two cases 193
A multicenter controlled, randomized, open trial of interferon alpha2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C 192
In vivo and in vitro effect of ribavirin and interferon on erythropoiesis in patients with hepatitis C 192
Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin 191
Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression 189
Liver cell proliferation and liver cancer risk in patients with hepatitis C virus-related cirrhosis under antiviral treatment 188
Trattamento della cirrosi epatica HCV-correlata 187
The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease : A cohort study 186
Suboptimal response to hepatitis B vaccine in drug users 186
The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophilic males : an international, multicenter study 186
Interferoni pegilati nel trattamento dei pazienti con epatite cronica HCV : esperienze a confronti 184
Standard and pegylated interferon alfa-2b plus ribavirin as initial treatment for HCV genotype 2 chronic hepatitis : analysis of a large single center cohort 183
Antiviral Therapy for HCV-Associated Cryoglobulinemic Glomerulonephritis : Case Report and Review of the Literature 181
Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma 181
Optimizing treatment with pegylated interferon-ribavirin of genotype 3 chronic hepatitis C : more questions than answers 180
Low risk of hepatitis B reactivation in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 180
Totale 24.186
Salva come PNG Salva come JPEG
Categoria #
all - tutte 91.362
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.362
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.935 0 0 69 127 139 161 225 192 238 277 157 350
2022/20232.426 323 269 204 281 260 482 46 125 270 23 106 37
2023/20241.790 45 115 77 142 529 118 129 107 59 93 153 223
2024/20253.578 155 414 63 412 270 114 103 342 207 322 336 840
2025/20268.533 844 437 810 569 710 530 1.169 443 729 572 938 782
2026/20271.229 592 584 53 0 0 0 0 0 0 0 0 0
Totale 33.621